Joachim Weis1, Krzysztof A Tomaszewski2, Eva Hammerlid3, Juan Ignacio Arraras4, Thierry Conroy5, Anne Lanceley6, Heike Schmidt7, Markus Wirtz8, Susanne Singer9, Monica Pinto10, Mohamed Alm El-Din11, Inge Compter12, Bernhard Holzner13, Dirk Hofmeister14, Wei-Chu Chie15, Marek Czeladzki16, Amelie Harle17, Louise Jones18, Sabrina Ritter19, Hans-Henning Flechtner20, Andrew Bottomley21. 1. Tumor Biology Centre, University Clinic Centre, Freiburg, Germany. 2. Faculty of Medicine, Jagiellonian University Medical College, Krakow, Poland. 3. Department of Otolaryngology Head and Neck Surgery, Sahlgrenska University Hospital, Gothenburg, Sweden. 4. Oncology Departments, Complejo Hospitalario de Navarra, Pamplona, Spain. 5. Department of Medical Oncology, Lorraine Cancer Institute, Nancy, France. 6. Institute for Women's Health, University College, London, UK. 7. Institute of Health and Nursing Science, Medical Faculty, Martin Luther University, Halle, Germany. 8. Department of Research Methods, University of Education, Freiburg, Germany. 9. Division of Epidemiology and Health Services Research, Institute of Medical Biostatistics, Epidemiology and Informatics, University Medical Centre, Mainz, Germany. 10. Rehabilitation Unit, Department of Health Policy, Farmacy and Quality of Life, Istituto Nazionale, Tumori "Fondazione Giovanni Pascale," IRCCS, Naples, Italy. 11. Department of Clinical Oncology, Tanta Faculty of Medicine, Egypt. 12. Department of Radiation Oncology (MAASTRO), GROW (School for Oncology and Developmental Biology), University of Maastricht Medical Center, Maastricht, The Netherlands. 13. Department of Psychiatry and Psychotherapy, Medical University of Innsbruck, Innsbruck, Austria. 14. Department of Medical Psychology and Medical Sociology, University of Leipzig, Germany. 15. Department of Family Medicine, National Taiwan University, Taiwan. 16. Research and Development Office, Southern Health NHS Foundation Trust, Southampton, UK. 17. Medical Oncology Department, The Christie NHS Foundation Trust, Manchester, UK. 18. HPB Services Directorate of Surgery, University Hospital Aintree, Liverpool, UK. 19. Institute of Research in Rehabilitation Medicine at Ulm University, Ulm, Germany. 20. Department of Paediatric Psychiatry, University of Magdeburg, Magdeburg, Germany. 21. Quality of Life Department, EORTC Headquarters, Brussels, Belgium.
Abstract
Background: The European Organisation for Research and Treatment of Cancer (EORTC) Group has developed a new multidimensional instrument measuring cancer-related fatigue to be used in conjunction with the quality of life core questionnaire (EORTC QLQ-C30). The module EORTC QLQ-FA13 assesses physical, cognitive, and emotional aspects of cancer-related fatigue. Methods: The methodology follows the EORTC guidelines for phase IV validation of modules. This paper focuses on the results of the psychometric validation of the factorial structure of the module. For validation and cross-validation confirmatory factor analysis (maximum likelihood estimation), intraclass correlation and Cronbach alpha for internal consistency were employed. The study involved an international multicenter collaboration of 11 European and non-European countries. Results: A total of 946 patients with various tumor diagnoses were enrolled. Based on the confirmatory factor analysis, we could approve the three-dimensional structure of the module. Removing one item and reassigning the factorial mapping of another item resulted in the EORTC QLQ-FA12. For the revised scale, we found evidence supporting good local (indicator reliability ≥ 0.60, factor reliability ≥ 0.82) and global model fit (GFI t1|t2 = 0.965/0.957, CFI t1|t2 = 0.976/0.972, RMSEA t1|t2 = 0.060/0.069) for both measurement points. For each scale, test-retest reliability proved to be very good (intraclass correlation: R t1-t2 = 0.905-0.921) and internal consistency proved to be good to high (Cronbach alpha = .79-.90). Conclusion: Based on the former phase III module, the multidimensional structure was revised as a phase IV module (EORTC FA12) with an improved scale structure. For a comprehensive validation of the EORTC FA12, further aspects of convergent and divergent validity as well as sensitivity to change should be determined.
Background: The European Organisation for Research and Treatment of Cancer (EORTC) Group has developed a new multidimensional instrument measuring cancer-related fatigue to be used in conjunction with the quality of life core questionnaire (EORTC QLQ-C30). The module EORTC QLQ-FA13 assesses physical, cognitive, and emotional aspects of cancer-related fatigue. Methods: The methodology follows the EORTC guidelines for phase IV validation of modules. This paper focuses on the results of the psychometric validation of the factorial structure of the module. For validation and cross-validation confirmatory factor analysis (maximum likelihood estimation), intraclass correlation and Cronbach alpha for internal consistency were employed. The study involved an international multicenter collaboration of 11 European and non-European countries. Results: A total of 946 patients with various tumor diagnoses were enrolled. Based on the confirmatory factor analysis, we could approve the three-dimensional structure of the module. Removing one item and reassigning the factorial mapping of another item resulted in the EORTC QLQ-FA12. For the revised scale, we found evidence supporting good local (indicator reliability ≥ 0.60, factor reliability ≥ 0.82) and global model fit (GFI t1|t2 = 0.965/0.957, CFI t1|t2 = 0.976/0.972, RMSEA t1|t2 = 0.060/0.069) for both measurement points. For each scale, test-retest reliability proved to be very good (intraclass correlation: R t1-t2 = 0.905-0.921) and internal consistency proved to be good to high (Cronbach alpha = .79-.90). Conclusion: Based on the former phase III module, the multidimensional structure was revised as a phase IV module (EORTC FA12) with an improved scale structure. For a comprehensive validation of the EORTC FA12, further aspects of convergent and divergent validity as well as sensitivity to change should be determined.
Authors: D Presti; J Havas; D Soldato; P Lapidari; E Martin; B Pistilli; C Jouannaud; G Emile; O Rigal; M Fournier; P Soulie; M-A Mouret-Reynier; C Tarpin; M Campone; S Guillermet; A-L Martin; S Everhard; A Di Meglio Journal: ESMO Open Date: 2022-06-17
Authors: Edvard Abel; Ewa Silander; Fredrik Nordström; Caroline Olsson; N Patrik Brodin; Jan Nyman; Thomas Björk-Eriksson; Eva Hammerlid Journal: Adv Radiat Oncol Date: 2022-04-08
Authors: T Veni; S Boyas; B Beaune; H Bourgeois; A Rahmani; S Landry; A Bochereau; S Durand; B Morel Journal: Support Care Cancer Date: 2018-06-24 Impact factor: 3.603
Authors: Ines Vaz-Luis; Antonio Di Meglio; Julie Havas; Mayssam El-Mouhebb; Pietro Lapidari; Daniele Presti; Davide Soldato; Barbara Pistilli; Agnes Dumas; Gwenn Menvielle; Cecile Charles; Sibille Everhard; Anne-Laure Martin; Paul H Cottu; Florence Lerebours; Charles Coutant; Sarah Dauchy; Suzette Delaloge; Nancy U Lin; Patricia A Ganz; Ann H Partridge; Fabrice André; Stefan Michiels Journal: J Clin Oncol Date: 2022-03-15 Impact factor: 50.717